Processing thousands of user suggestions monthly through its official feedback channel, the global blockchain ecosystem underscores its commitment to user-driven innovation by introducing various enhancements and updates across various products 

MANAMAN, Bahrain, Dec. 11, 2023 /PRNewswire/ — Binance, the global blockchain ecosystem behind the largest cryptocurrency exchange by trading volume, is happy to share that a total of 246 feature suggestions received from users via its Feature Request & Feedback Board were validated in November this year. This user-focused feedback process is part of Binance’s dedication to its community, and is a key element for why Binance has been able to keep building and improving over the years.

Each month, the product teams at Binance carefully review and evaluate thousands of users’ feedback, suggestions and ideas. Doing so offers valuable insights for Binance as the organization continues to roll out the next generation of products, with its users and their needs at its core.

Key enhancements and updates made in November 2023 include:

Elevating users’ P2P experience: Making P2P transactions on Binance has become more user-friendly, secure and accessible than ever before. Notable enhancements include: introduction of mobile web for the P2P Merchant Portal, ability to pin selected P2P featured ads at the top of the marketplace, and support for video uploads in the P2P chat. These enhancements provide increased convenience and functionality to the Binance P2P platform, thereby boosting both users’ and merchants’ P2P trading experience. Streamlining users’ financial transactions: Binance’s deposits and withdrawals processes have gone through several updates, resulting in increased flexibility, clarity and convenience for users when managing their funds. For instance, users can now choose both spot and funding wallets during the crypto withdrawal process. Users benefit from quicker and more convenient fund management due to this streamlining. Binance has also introduced a new confirmation step on the crypto deposit page to help minimize errors and create a simplified process. Enhancing users’ trading through intuitive dashboards: The dashboards on Binance have been revamped, simplified and optimized to enhance clarity and ease of use. The newly designed interfaces on both web and app platforms make it easier for users to navigate market trends, manage assets, and execute transactions in a simplified and personalized way. In the case of the Market and Assets dashboards, for instance, the new design intentionally focuses on essential information only. Users are thus able to easily track market trends and make informed decisions without the distraction of unnecessary elements.

In addition to the enhancements and updates covered above, there are many other releases by the Binance team in November. A list of some of these other releases are as follows:

User interface and trading tools: sidebar integration, internal transfer page optimization, security settings integration, deposit and withdrawal details with CS bot, kline enhancements P2P and wallet features: P2P new user coach on Lite version, cashlink mint/burn process for P2P, revoke messages in P2P chat room, wallet history enhancements Copy Trading enhancements: support API trading for lead traders, privacy options for lead traders, addition of copy trading on Market Discover page Futures trading enhancements: Futures price alert, new BBO order type, clearer fee info on position history, one-stop derivative data info page Options trading enhancements: T-shaped quote in Binance Pro, Options heat map

The updates and enhancements shared above are just a glimpse of the many improvements made by Binance in November. Each of these developments, from the user-friendly P2P transaction features, the streamlined deposits and withdrawals process, and the refined dashboards, reflects the organization’s ongoing commitment to its users and community.

For the latest updates to Binance’s product suite, do look out for weekly #BinanceBuild updates on the organization’s official social channels. Monthly #BinanceBuild recaps will also be posted on Binance Blog.

Disclaimer: The products and services referred to herein may be restricted in certain jurisdictions or regions or to certain users, in accordance with applicable legal and regulatory requirements. These materials are intended only for those users who are permitted to access and receive the products and services referred to and are not intended for users to whom restrictions apply. You are responsible for informing yourself about and observing any restrictions and/or requirements imposed with respect to the access to and use of any products and services offered by or available through Binance in each country or region from which they are accessed by you or on your behalf. Binance reserves the right to change, modify or impose additional restrictions with respect to the access to and use of any products and/or services offered from time to time in its sole discretion at any time without notification.

Source : Binance Demonstrates Commitment to User-Led Innovation, Validated Over 240 User Suggestions in November 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Dec. 11, 2023 /PRNewswire/ — Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has renewed its service agreement (the "Agreement") with Beijing Public Health Foundation ("BPHF"), a non-profit organization dedicated to enhancing Chinese citizens’ health through public welfare initiatives and aid programs. Pursuant to the Agreement, Zhongxin and BPHF extended its partnership to work together on a patient aid project (the "Project") to provide medication assistance services for cancer patients.

The Project offers free Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi’s sarcoma, ovarian cancer, osteosarcoma, and myeloma based on their needs. The Project aims to ensure patients to have longer lasting and more effective medical treatments with less financial burden. The Project operates through over 300 hospitals and 100 pharmacies, where qualified cancer patients after an assessment can receive their medications for free. To date, the Project has been in operation for three years, serving over 6,000 patients and donating more than 22,000 doses of medication.

Under the supervision and guidance of BPHF, Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for providing staff with training and daily operation management, maintaining the project website,  management for patients, and monitoring and analyzing project progress. These efforts aim to standardize the workflow and enhance the operational efficiency of the Project. Additionally, the platform also performs information management for Project participants, such as hospitals and pharmacies, to improve operational efficiency and accuracy.

With the rising incidence of cancer and prolonged life expectancy brought by new technologies, the cost of innovative medications and long-term treatments has intensified financial burden on patients. Zhongchao believes that the Project encourages and supports patients in need to adhere to sustained treatments with significant therapeutic effects and less financial burden on families. Zhongchao remains committed to leveraging its service capabilities and experience in enhancing treatment efficiency and quality of life for cancer patients.

About Zhongchao Inc.

Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It consolidates the financial results of a variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the "PRC operating entities") through a series of contractual arrangements. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (www.mdmooc.org), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at http://izcmd.com. 

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

At the Company: Pei Xu, CFO
Email: [email protected]
Phone: +86 13901629242

Investor Relations: Sherry Zheng
Weitian Group LLC
Email: [email protected]
Phone: +1 718-213-7386

Source : Zhongchao Inc. Collaborates with a Public Health Foundation to Support Sustainable and Effective Cancer Treatments

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

The world’s largest IT-Home Appliance Trade Show, "CES 2024" in Las Vegas, Nevada.  APR Corps will participate under the category of ‘lifestyle’  First participation ever since its establishment  Plans to reveal new products for U.S. launch in addition to currently exporting products Beauty Device Technology will be the key for global including the United States 

SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ — APR Corp. (APR, CEO Byunghoon ‘Victor’ Kim), the global beauty-tech company, is ready to present K-Beauty Tech based on beauty devices at the world’s largest IT-Home Appliance Show, CES 2024.

Medicube Age-R Booster Pro

APR announced its participation in CES 2024, which will be held at the Las Vegas Convention Center in Las Vegas, Nevada, U.S., from Jan 9th to 12th, 2024. CES, hosted by the Consumer Technology Association (CTA) in the U.S., is the world’s largest home appliance trade show, recently attracting global companies from various industries to showcase their technologies.

This year’s CES marks APR’s first participation and the company will introduce its ‘medicube AGE-R’ beauty devices that create a new skincare lifestyle, under the Show’s Lifestyle category. To this end, six products that have already been successful in the U.S. market, Derm EMS, Ussera Deep Shot, ATS Air Shot, Booster-H, i-Shot, and Contour Body Shot, are set to be showcased initially. Visitors to the APR booth would experience ‘how to care’ with these beauty devices through visual materials.

Medicube Age-R 5 types

APR will also unveil soon-to-be-released products that showcase its technological prowess. Particularly, the next-generation device ‘Booster Pro,’ launched in Korea last Oct, is expected to earn attention in the U.S. as well. Booster Pro represents the culmination of APR’s accumulated know-how in beauty device technology since its brand launch in 2021. The product has gained high popularity in South Korea since its release because of the variety of skincare benefits such as more radiant skin, enhanced skin elasticity, and effective pore management in one device.

APR expects to establish its global reputation as a leading beauty tech company representing South Korea through this year’s CES. APR has continued to engage in skin science research and remains dedicated to securing innovative technological capabilities. This year, in particular, APR established the APR Device Center (ADC), a specialized research and development center for beauty device technology, focusing on enhancing R&D capabilities in beauty devices and internalizing core technologies. APR’s beauty device technology is becoming a key driving force in the global market strategy, and as of last November, domestic (South Korea) and international beauty device sales surpassed 1.5 million units.

Byunghoon ‘Victor’ Kim, CEO of APR, stated, "We are extremely proud to showcase APR’s technology at CES, the world’s largest consumer electronics trade show." Mr. Kim added, "Through this exhibition, we aim to expand APR’s brand name recognition as South Korea’s leading beauty-tech company to consumers worldwide."

CES 2024 has completed registrations of global companies from over 150 countries, with more than 200,000 visitors expected to attend during the exhibition period.

Source : "K-Beauty Tech Shines in the U.S." APR Corp. to Showcase Beauty Device Technology at CES 2024

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Company to Pursue Full Separation of IoT and Cybersecurity Business Units

Industry veteran Giamatteo to lead BlackBerry as Chief Executive Officer IoT and Cybersecurity business units to become fully standalone BlackBerry divisions Process underway to separate centralized functions and right-size cost structures Company will no longer pursue subsidiary IPO of IoT business New organization structure to present greater options for enhancing shareholder value

WATERLOO, ON, Dec. 11, 2023 /PRNewswire/ — BlackBerry Limited (NYSE: BB; TSX: BB) today announced the appointment of John J. Giamatteo as its new Chief Executive Officer and as a member of its Board of Directors, effective immediately. Richard (Dick) Lynch, who has served as interim Chief Executive Officer since November 4, 2023, will continue as Board Chair. The Company also announced that it will separate the IoT and Cybersecurity businesses, and that they will operate as fully standalone divisions. BlackBerry will no longer pursue a subsidiary IPO of the IoT business.

Appointment of John J. Giamatteo as BlackBerry CEO

Giamatteo has served as the President of BlackBerry’s Cybersecurity business unit since October 2021.

Giamatteo has over 30 years of experience with global technology companies.  As President of BlackBerry’s Cybersecurity business unit, he has driven significant enhancements to the product portfolio, go-to-market strategy and organizational efficiency. Prior to BlackBerry he was President and Chief Revenue Officer at McAfee.  Before that, John served as Chief Operating Officer at AVG Technologies, a leading provider of internet and mobile security. He also held leadership positions with Solera, RealNetworks and Nortel Networks.

"We are delighted to appoint John to the role of CEO for what will be a transformative period in BlackBerry’s history, as we work to fully separate our two core business units to drive enhanced shareholder value.  His deep industry experience and outstanding track record of inspiring teams and delivering operational excellence means he is strongly positioned to drive this critical transformation of BlackBerry," said Mike Daniels, Chair of the Compensation, Nomination and Governance Committee of the BlackBerry Board.

"I am honored and excited to lead the next phase of BlackBerry’s evolution as its CEO. BlackBerry’s IoT and Cybersecurity businesses have market-leading technology, exceptional teams and large market opportunities," said John J. Giamatteo. "The Board and I are fully aligned on the next steps needed to unlock the value within BlackBerry, and work on this effort will proceed at full speed. I look forward to working with the entire team to uphold our legacy of innovation and continue providing exceptional service to our customers as we deliver on our goals."

Reassessment of Strategic Direction

Following a reassessment of the previously announced outcome of Project Imperium, the BlackBerry Board has decided to pursue a separation of the IoT and Cybersecurity businesses and establish them as standalone divisions. The Company will no longer pursue a subsidiary initial public offering of its IoT business unit.  The process will include the separation and streamlining of BlackBerry’s centralized corporate functions into business-unit specific teams, with a view to each division operating independently and on a profitable and cashflow-positive basis going forward.

"The Board, with input from its advisors, believes that a full separation of BlackBerry’s IoT and Cybersecurity businesses will open up a number of strategic alternatives that can unlock shareholder value," said Dick Lynch, Board Chair, BlackBerry. "Management is focused on moving quickly to complete this reorganization that will further enhance the focus of both businesses on their respective markets as well as their capacity for fast, flexible decision-making."

To assist in the separation and right-sizing process, BlackBerry is in the final stages of selecting a consulting firm to bring expertise and additional resources for an independent, ground-up assessment.

About BlackBerry

BlackBerry (NYSE: BB; TSX: BB) provides intelligent security software and services to enterprises and governments around the world. The company secures more than 500M endpoints including over 235M vehicles. Based in Waterloo, Ontario, the company leverages AI and machine learning to deliver innovative solutions in the areas of cybersecurity, safety, and data privacy solutions, and is a leader in the areas of endpoint security, endpoint management, encryption, and embedded systems.  BlackBerry’s vision is clear – to secure a connected future you can trust.

For more information, visit BlackBerry.com and follow @BlackBerry. 

Investor Contact:

BlackBerry Investor Relations
+1 (519) 888-7465
[email protected] 

Media Contact:
BlackBerry Media Relations
+1 (519) 597-7273
[email protected]

This news release contains forward-looking statements within the meaning of certain securities laws, including under the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including statements regarding BlackBerry’s plans, strategies and objectives including its expectations with respect to increasing and enhancing its product and service offerings, and other statements that are not historical facts.

The words "expect", "anticipate", "estimate", "may", "will", "should", "could", "intend", "believe", "target", "plan" and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by BlackBerry in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that BlackBerry believes are appropriate in the circumstances, including but not limited to, BlackBerry’s expectations regarding its business, strategy, opportunities and prospects, the launch of new products and services, general economic and financial market conditions, competition, and BlackBerry’s expectations regarding its financial performance.  Many factors could cause BlackBerry’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation: risks related to the proposed separation disrupting BlackBerry’s operations and making it more difficult to conduct business as usual, including maintaining relationships with customers, channel partners or other third parties; risks and uncertainties related to BlackBerry’s ability to complete a full separation of its IoT and Cybersecurity business units on the anticipated timelines, or at all; risks related to BlackBerry’s ability to operate the IoT and Cybersecurity businesses on a profitable or cashflow-positive basis or to enhance shareholder value as a result; and the risks discussed in BlackBerry’s Annual Report on Form 10-K and the "Cautionary Note Regarding Forward-Looking Statements" section of BlackBerry’s MD&A (copies of which filings may be obtained at www.sedar.com or www.sec.gov). All of these factors should be considered carefully, and readers should not place undue reliance on BlackBerry’s forward-looking statements. Any statements that are forward-looking statements are intended to enable BlackBerry’s shareholders to view the anticipated performance and prospects of BlackBerry from management’s perspective at the time such statements are made, and they are subject to the risks that are inherent in all forward-looking statements, as described above, as well as difficulties in forecasting BlackBerry’s financial results and performance for future periods, particularly over longer periods, given changes in technology and BlackBerry’s business strategy, evolving industry standards, intense competition and short product life cycles that characterize the industries in which BlackBerry operates. Any forward-looking statements are made only as of today and BlackBerry has no intention and undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by applicable law.

Source : BlackBerry Appoints John Giamatteo as CEO

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study

SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ — Shanghai Yingli Pharmaceutical Co., Ltd. ("Yingli Pharma"), a biopharmaceutical company focused on developing oral therapies for cancer and metabolic diseases, today announced the pivotal Phase 2 clinical trial results of the investigation of linperlisib in the treatment of patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). Linperlisib is a phosphoinositide 3-kinase delta (PI3Kδ) oral inhibitor, approved in China for treatment of patients with r/r follicular lymphoma after systemic therapy. 

"There is a vital need for new therapies to treat highly aggressive cancers such as r/r PTCL where there are very limited treatment options." said Dr. Jun Zhu, Professor, Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China, who was the leading investigator for this pivotal clinical trial. "In addition to the promising efficacy and well manageable safety of linperlisib in r/r PTCL, it is noteworthy that a high proportion of the treated patients were shown to have a complete response, and responses have been seen in all the major PTCL subtypes."

"Our approach is to develop novel oral agents that will allow patients to safely administer at home," said Michael Hui, CEO of Yingli Pharma, "We are delighted that the encouraging results of this study support the use of linperlisib in this hard-to-treat disease and are excited to continue developing linperlisib in more indications. The company has applied for linperlisib marketing approval in r/r PTCL in China based on these pivotal study findings." Mr. Hui added, "We look forward to the results of an ongoing open-label multi-center Phase 2 study in the U.S. and Italy in r/r PTCL and r/r CTCL." 

Safe and effective treatment of r/r PTCL patients

The pivotal r/r PTCL Phase 2 clinical trial enrolled 98 patients (pts) from May 2021 to October 2022 at 25 clinical sites in China. The pts had a median of two lines of prior systemic therapies. Sixty-four pts (73%) had refractory disease, 59 pts (67%) had relapsed disease, and 35 pts (40%) had both relapsed and refractory diseases. All patients received linperlisib at 80 mg QD, the RP2D for the drug, with a minimum of 6 months follow-up.

The linperlisib-treated patients (Full Analysis Set N = 88) evaluated by Lugano criteria, had a 48% overall response rate, including 30% complete responses and 18% partial responses, as well as a 68% disease control rate. The median Duration of Response was not reached although the 6-month DOR rate was 75%. The median PFS was 5.5 months (95% CI, 3.5, 15.6) and the median OS was 14.2 months (95%CI, 7.9, not reached). Responses were observed across PTCL subtypes.

Linperlisib was well tolerated with a differentiated and manageable safety profile, specifically having very low levels of immune-mediated toxicities. In the linperlisib-treated patient safety dataset (N=98) for the pivotal study, the most common hematologic treatment related adverse events (TRAEs) of Grade≥3 were neutropenia (32%), leukocytopenia (10%), Anemia (6%), Thrombocytopenia (5%), and Lymphocytopenia (5%). The most common nonhematologic TRAEs of Grade≥3 were pneumonia (14%) and upper respiratory tract infection (5%). Immune-mediated Grade≥3 TRAEs including elevated ALT, AST, diarrhea, colitis, rash were not reported or were <5%. Nine patients (9.2%) discontinued from the study due to various adverse events. The safety results of this study were consistent with previously reported data in other linperlisib clinical studies.

About linperlisib

Linperlisib, a next-generation PI3K-selective oral inhibitor, received marketing approval in China in 2022 for treatment of patients with relapsed and/or refractory follicular lymphoma after two or more systemic therapies. Linperlisib also received U.S. FDA Orphan Drug Designations for follicular lymphoma, chronic lymphocytic leukemia, and T cell lymphomas. 

Linperlisib is under investigation in multiple additional clinical trials as a monotherapy: frontline PTCL, r/r large granular T lymphocytic leukemia, r/r autoimmune hemolytic anemia; and in combination with other agents: in second line follicular lymphoma and marginal zone lymphoma, frontline PTCL, and r/r CTCL.  In the U.S. and EU, linperlisib is being developed by 280Bio, Inc (San Francisco, CA., USA), a wholly-owned subsidiary of Yingli Pharma, in a Phase 2 clinical study in r/r T Cell Lymphomas [PTCL and CTCL].

About Yingli Pharma

Shanghai Yingli Pharmaceutical Co., Ltd., founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang InnoPark, is a clinical-stage biotechnology company developing oral drugs for oncology and metabolic diseases. Yingli Pharma has partnered with Jiangsu Hengrui Pharmaceuticals Co., Ltd., for Greater China commercialization of linperlisib (Intarel®) in r/r follicular lymphoma that is conditionally approved, and other heme indications. Yingli Pharma is currently developing other oral agents in clinical stage from its oncology portfolio, including YL-13027 (TGFR1 inhibitor), YL17231 (pan-RAS inhibitor), YL-15293 (KRASG12C inhibitor), as well as a rich pipeline of additional novel oral agents in oncology.

For more information, please see: http://www.yl-pharma.com/

Source : Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Dec. 11, 2023 /PRNewswire/ — China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual property ("IP") incubation platform in China, today announced that it has entered into an Asset Transfer Agreement with Tencent Holdings Limited ("Tencent", stock code: 0700) to acquire the related assets of Tencent Animation and Comics, including among others Tencent Animation and Comics’ APP platform, the intellectual property rights and related rights to its content, and its animation, film and TV series projects, for an aggregate cash consideration of RMB600 million. 

Established in 2012, Tencent Animation and Comics is a leading animation and comic platform in China. It has nurtured an ecosystem for animation and comic creators and consumers, and incubated top-tier IPs including The Outcast, The Fox Spirit Matchmaker and Spare Me, Great Lord!. Among these, the comic title The Outcast has a popularity index of 30 billion and a rating of 9.8 out of 10 on the Tencent Animation and Comics platform, and its adapted animation series has accumulated over 6.5 billion video views. In addition, its adapted TV series I Am Nobody has been a standout success, gaining a popularity index of more than 10,000 on the Youku platform and a Douban rating of 8.1 out of 10. Another popular title, The Fox Spirit Matchmaker, has been added to 5.5 million users’ reading lists on the Tencent Animation and Comics platform, and the adapted animation series has received over 11 billion video views. Its upcoming TV adaptation, The Fox Spirit Matchmaker Yuehong, is expected to be released in 2024, and has already garnered more than 3 million pre-registrations on the iQIYI platform.

Mr. Hou Xiaonan, Chief Executive Officer of China Literature, commented, "China Literature and Tencent Animation and Comics share a rich history of collaboration which has yielded remarkable accomplishments. It is worth noting that approximately 50% of Tencent Animation and Comics’ top 30 best-selling titles originate from China Literature’s IPs. Online literature has served as a rich vein of storytelling material for successful comics and animation, while comics and animation have created vivid imagery to accompany stories from our platform, significantly enhancing the IP value of the original written works. I am truly thrilled to welcome Tencent Animation and Comics into the China Literature family. This acquisition will enrich China Literature’s reservoir of blockbuster IPs, bolster our pipeline of comic adaptations, and further expand our production capacity for animation. We expect this alliance to become a key driver of China Literature’s future growth, and through robust synergies, we believe the combined entity will create more value than either party could achieve individually. Looking ahead, China Literature intends to leverage artificial intelligence technologies to empower the adaptation of online literature into animation and comics, accelerating the visualization process of text-based IPs and thereby enhancing the efficiency of our IP commercialization efforts."

About China Literature Limited

China Literature is dedicated to building a deep and immersive intellectual property ("IP") universe for the Mandarin-speaking world. It incubates original IPs from its online literature platform, which are subsequently adapted on a range of digital entertainment mediums, including comics, animation, film, TV series, web series and games. The virtual world created by these digital offerings become an inseparable part of a user’s daily life. China Literature creates and promotes IPs mainly through Qidian Reading and QQ Reading, its leading online literature platforms, as well as New Classics Media, a renowned film and TV drama series production house in China. China Literature collaborates with Tencent, its shareholder and strategic partner, as well as other third-party partners to distribute and develop IP content and to enhance value of its IP. Many of the Company’s online literature works have been successfully adapted into animation, TV series, web series, film and games, including Joy of Life, Candle in the Tomb, Soul Land, The King’s Avatar and My Heroic Husband. China Literature’s rich and extensive content library as well as its unparalleled capability and resources to adapt IP into various entertainment formats is a significant competitive advantage that lies at the core of its business model. For more information, please visit http://ir.yuewen.com/.

Contact

For investors / analysts:
Maggie Zhou
Tel: +8621 6187 0500 ext. 80605
Email: [email protected] 

For media:
Vivian Wang
Tel: +852 2232 3978
Email: [email protected]

Forward-Looking Statements

This press release contains forward-looking statements relating to the industry and business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in our other public disclosure documents on our corporate website.

Source : China Literature to Acquire Tencent Animation and Comics

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BEIJING, Dec. 11, 2023 /PRNewswire/ — When Luc Besson’s latest film Dogman hits Chinese cinemas, it is expected to further boost the rebounding Chinese box office so far dominated by domestic films throughout 2023.

While his previous offering – Valerian and the City of a Thousand Planets – is remembered for its cosmic adventure and an interplanetary fashion extravaganza, Dogman is to move the audiences with the captivating theme of fortitude amid life’s vicissitudes when it becomes available at Chinese cinemas on December 15.

During its screening at the Pingyao International Film Festival in October in Shanxi Province, the film moved the 1,500-stong audience to tears. It was Besson’s first trip to China after six years. He also expressed his emotions publicly, touched by the audience’s heartfelt reaction when the film concluded. "I was sitting in the first row. I could feel their tears. When the film finished, they gave me so much appreciation," Besson told the Global Times during an interview in Beijing.

It was reported that the director was also moved to tears when the audience in Venice gave the showing a six-minute-long applause at the end.

Having seen his own film many times, Besson admits he sometimes still gets caught up in its emotion.

Besson wrote the script in which the protagonist, a young man named Douglas, develops a bond with dogs and seeks revenge on his abusive father. Having been the victim of mistreatment at home, Douglas becomes disillusioned with the human world, and only the love of his dogs can bring salvation.

Help people in pain

The idea of making this story into a film came when the director read an article about a father who caged his son for years. "I was trying to imagine how this kid survived; how did he get out of the cage; what he’s gonna become. He can become very bad or very good. That’s his choice," he said.

While the movie is about pain, Besson presents his preferred version of what the young man could become despite the pain.

Agreeing with the ancient Chinese saying "Man is born good," Besson said "people are born good, and sometimes they become bad because of the circumstances."

"No matter what your pain is, it’s your choice to make it good. I really want to spread this message: You can help people in pain," he said.

Besson gives Caleb Landry Jones high praises for his excellent performance. "On a scale from 0 to 10, I will give him 25. I wish I will be lucky enough to make more films with him."

Other main actors in the film, however, are far less easy to cooperate with.

Casting the dogs is in itself a fun and difficult task. First, they collected all the pictures of the dogs and tried to put the pictures next to each other, in order to form a team with enough diversity, to have every kind of dogs in the film as "a reflection of the entire world."

In terms of managing the dogs to have them perform, "you try to organize miracles with the dogs, and you have to be very patient. You have to know them and learn, and do the best that you can to organize this mess."

Booming industry

Having won high recognition in China for his previous works, Besson told the Global Times that he never reads viewers’ comments about what he makes. "Everyone has opinions, good or bad. I’m not hiding from the bad ones, [but I’m] not looking for the good ones, either."

His passion lies solely in making the film, not in the conversation of viewers. He took the Forbidden City as an example, describing it as "one of the most amazing architecture I’ve ever seen."

"Do you think at the time people built it, they would think a French man would come and say ‘OMG, it’s wonderful!’"

"A 60-year-old man in China, or a 13-year-old girl in Germany will all watch the film. They are not of the same culture or age. Someone not born today will watch Dogman in 20 years, and I’m probably not there," he said. "I just hope they will take something from the film."

Having not been in China for six years, Besson observed changes in the Chinese filmmaking industry during his visit in October. He met with leading Chinese directors and actors like Ning Hao and Huang Xuan in Pingyao, and saw a booming industry with a lot of energy, predicting that the Chinese film market is likely to become the world’s biggest in a few years once again.

The film box office in 2023 has seen a fast rebound after the pandemic, reaching more than 50 billion yuan ($7.01 billion) as of mid-November.

Staying in China for almost 10 days in October, Besson came back to China again and appeared for promotional events in Shanghai over the weekend. For Besson, Chinese culture is full and complex. "I want to spend more time to know people here better; to talk to people."

He is also open to cooperating with Chinese film producers. With a lot of experience himself, Besson said he would be very happy to help younger directors, and probably "steal" some energy from the young people.

Source : Global Times: Renowned French director Luc Besson brings latest work 'Dogman' to China

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network